Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam
Saved in:
| Published in: | Thoracic Cancer |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam
- Nomogram integrating MRI radiomics and white matter hyperintensity grading for predicting overall survival in patients with non‐small cell lung cancer and brain metastases receiving whole‐brain radiotherapy
- Brain metastases in non-small cell lung cancer: Prevalence, high-risk factors, and overall survival prognosis
- Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices
- Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol
- Prognostic Impact of ALK on Anaplastic Large Cell Lymphoma of CNS
- Selective internal radiotherapy and chemosaturation show equivalent survival in metastatic uveal melanoma: a retrospective multicenter study